IQVIA (IQV) Q1 FY26 earnings call: guidance and Q&A

How does the mix of services vs. pass-through bookings impact margin progression, especially with more full-service wins in R&DS?

Ari Bousbib clarified that pass-throughs have zero profitability and are irrelevant to margins. The low pass-through bookings in Q1 were due to a specific mix of indications in trials won, not a change in customer dynamics. He noted that pure service fee bookings were up significantly and that quarterly book-to-bill is a poor predictor of future growth. Mike Fedock added that productivity programs offset adverse mix, leading to operational margin expansion.

“pass has 0 profitability drop through, right? I mean that's clear. So pass-throughs are irrelevant to profitability.”

asked by Michael Cherny · answered by Ari Bousbib

Is the FSO dynamic with less pass-throughs a function of customer clinical strategy or a shift from large pharma? Will this impact margins this year or beyond?

Ari Bousbib reiterated that the lower pass-throughs were due to the specific trial mix in the quarter, not a change in customer strategy. He emphasized that one quarter of bookings doesn't make a trend and won't affect margins. He also noted that the fundamental drivers for outsourced clinical development remain strong, with no change in the constructive demand environment from large pharma, despite slower decision-making.

“It just happens to be that trials that we won this quarter had lower price had nothing to do with a change in customer dynamic.”

asked by Justin Bowers · answered by Ari Bousbib

Where is IQVIA seeing actual growth acceleration versus stabilization? Is IQVIA's performance indicative of market growth or improved win rates?

Ari Bousbib stated that the company was surprised by its strong performance, calling it an "extremely clean quarter" with beats on all financial metrics. He noted that AI is a tailwind, creating new demand. Large pharma is more constructive, especially on the commercial side, though R&D decision-making is still slower than pre-disruption. EP funding is at record levels, indicating renewed confidence. He believes AI at the discovery stage will increase the number of trials and demand for CRO services.

“large [indiscernible] clients told us actually, if I can share that anecdotes, that they plan to double the number of molecules in their pipeline because they are using AI to identify more targets.”

asked by Shlomo Rosenbaum · answered by Ari Bousbib

What are the drivers of EBITDA margin, particularly for Q2, and how should we think about it for the back half of the year?

Mike Fedock stated that the implied EBITDA progression in guidance is consistent with history. He noted that Q1 had the largest FX headwinds, which will moderate later in the year. He expressed confidence that reported margins will turn positive as the year progresses due to strong productivity programs.

“Q1 has the largest FX teens and you'll see that start to moderate as we go through the back end of the year.”

asked by Elizabeth Anderson · answered by Michael Fedock

Confirming the logic that if Q1 pass-through bookings were normal ($750M instead of $250M), the book-to-bill would be around 1.15.

Ari Bousbib confirmed the analyst's calculation, agreeing that the logic was consistent with what they were trying to express.

“Eric, you're amazing. The answer to your question is yes.”

asked by Eric Coldwell · answered by Ari Bousbib

Request for solid organic growth numbers for Commercial Solutions and R&DS on a recast basis.

Ari Bousbib provided the organic growth rates: 3% for R&DS (up from 1% a year ago) and 5% for Commercial Solutions (double last year's rate). He also stated 4% organic growth for the enterprise.

“3% organic for R&DS, 5% organic for commercial, 4% for the enterprise.”

asked by Eric Coldwell · answered by Ari Bousbib